Last reviewed · How we verify
NCT06699368: UHP-POP-ESO
Clinical Study on the Risk of Left Atrial POP Ablation and Esophageal Injury Under Ultra-High Power and Related Influencing Parameters
NA trial testing The ultra-high-power ablation group in Ultra-High Power Ablation,Safety of Atrial Fibrillation Ablation in 120 participants. Not yet recruiting.
5 May 2025
Quick facts
| Lead sponsor | The Third People's Hospital of Chengdu |
|---|---|
| Phase | NA |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | prevention |
| Enrollment | 120 |
| Start date | 28 November 2024 |
| Primary completion | 5 May 2025 |
| Estimated completion | 5 June 2025 |
Drugs / interventions tested
- The ultra-high-power ablation group
- The high-power ablation group
Conditions studied
- Ultra-High Power Ablation,Safety of Atrial Fibrillation Ablation — all drugs for Ultra-High Power Ablation,Safety of Atrial Fibrillation Ablation →
Sponsor
The Third People's Hospital of Chengdu
Who can join
Adults 18 to 85, any sex, with Ultra-High Power Ablation,Safety of Atrial Fibrillation Ablation. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study aims to evaluate the risks of steam pop (POP) and esophageal injury, as well as related influencing parameters, under ultra-high power ablation technology. In the treatment of arrhythmias such as atrial fibrillation, cardiac ablation surgery is a common method. The use of ultra-high power ablation technology can shorten the operation time and improve effectiveness, but it may also increase the risk of damage to surrounding structures such as the esophagus. We will recruit a certain number of patients who are scheduled to undergo ultra-high power ablation surgery. We will record various parameters during the surgery, such as energy, time, and contact force, and monitor patients for signs of esophageal injury after the surgery. We expect that through this study, we can better understand the potential risks of ultra-high power ablation to the esophagus and identify the key parameters affecting these risks. This will help to improve surgical techniques, reduce complications, and enhance patient safety and surgical outcomes.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06699368
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other The Third People's Hospital of Chengdu trials
Trials by the same sponsor.
- NCT07321002 — PFLotus With the DePolar Mapping System in Patients With Persistent Atrial Fibrillation · NA · not yet recruiting
- NCT07301190 — FIH Study of PFLotus in Persistent Atrial Fibrillation · NA · recruiting
- NCT06811194 — PRIor Myocardial Infarction Identification on Electrocardiogram · enrolling by invitation
- NCT06694610 — A Study on the Relationship Between Individualized Low Voltage Regions in Left Atrium and the Mechanism of Atrial Fibril · NA · not yet recruiting
- NCT06652750 — Evaluating the Safety and Effectiveness of 5G Cloud Follow-up for Cardiovascular Implantable Electronic Devices · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06699368 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by The Third People's Hospital of Chengdu
- Last refreshed: 21 November 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06699368.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing